University of Arkansas January 2012
Use of generic drugs can save both you and your health plan money. This list is not all-inclusive and is not a guarantee of coverage. Plan Benefit design is the final determinate of coverage. Certain drugs (*) may be subject to Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST), or Reference Based Pricing (RBP) requirements according to Benefit Design. Branded products with an available generic equivalent may be subject to the highest copayment1 according to Benefit Design. If you have any questions about these requirements or other formulary questions, please contact a MedImpact Healthcare customer service representative at 800-788-2949. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics.
Drug Type Anti-Infectives cefditoren,cefuroxime, cephalexin ciprofloxacin, ciprofloxacin ext-rel, hyclate, minocycline, tetracycline acyclovir, famciclovir, valacyclovir Cardiovascular enalapril, fosinopril, fosinopril-University of Arkansas January 2012 Drug Type atenolol, carvedilol, carvedilol ext-rel, propranolol, propranolol ext-Central Nervous System donepezil,galantamine, rivastigmine University of Arkansas January 2012 Drug Type amitriptyline, bupropion/-ext-rel,
RBP: PLAN WILL PAY $0.19/PILL; REMAINING COST WILL BE APPLIED TO
REFERENCE BASED PRICING zolpidem tartrate ER* (QL,RBP),AMBIEN* (QL,RBP), AMBIEN CR* (QL,RBP),
PROGRAM (RBP)
EDLUAR*(QL,RBP),LUNESTA* (QL,RBP), ROZEREM* (QL,RBP),
SILENOR*(QL,RBP),SONATA* (QL,RBP), ZOLPIMIST*(RBP)
RBP: PLAN WILL PAY $0.09/PILL; REMAINING COST WILL BE APPLIED TO
REFERENCE BASED PRICING orphenadrine (RBP), orphenadrine compound (RBP), metaxalone (RBP),PROGRAM (RBP)
AMRIX (RBP), FEXMID (RBP),FLEXERIL(RBP), NORFLEX(RBP),
NORGESIC(RBP), NORGESIC FORTE (RBP), ROBAXIN (RBP), SKELAXIN
Dermatologicals Endocrine University of Arkansas January 2012 Drug Type $0 copay for Glucose Test Strips, Lancets, Alcohol Swabs, Insulin Gastrointestinal/Urinary cimetidine, famotidine, nizatidine,
RBP: PLAN WILL PAY $0.64/PILL; REMAINING COST WILL BE APPLIED TO
REFERENCE BASED PRICING
ACIPHEX* (QL,RBP), DEXILANT* (QL,RBP), lansoprazole*(QL,RBP), NEXIUM*
PROGRAM (RBP)
(QL,RBP), omeprazole-sodium bicarbonate* (QL,RBP), pantoprazole* (QL,RBP),
PREVACID* (QL,RBP), PRILOSEC* (QL,RBP), PROTONIX* (QL,RBP),
bethanechol, oxybutynin chloride,
RBP: PLAN WILL PAY $0.30/PILL; REMAINING COST WILL BE APPLIED TO
REFERENCE BASED PRICING trospium (RPB), DETROL (RPB), DETROL LA (RPB), DITROPAN (RPB),
PROGRAM (RBP) oxybutynin ext-rel (2nd Tier
DITROPAN XL (RPB), GELNIQUE (RPB), OXYTROL (RPB), SANCTURA (RPB),
Copay)
SANCTURA XR (RPB), TOVIAZ (RPB), VESICARE (RPB)
Immunosuppressive Agents Men’s Health Ophthalmics University of Arkansas January 2012 Drug Type betaxolol, brimonidine, dipivefrin, metipranolol, pilocarpine, timolol, Respiratory
RBP: PLAN WILL PAY $22.42/inhaler; REMAINING COST WILL BE APPLIED
REFERENCE BASED PRICING triamcinolone* (QL,RBP),ASTELIN* (QL), ASTEPRO* (QL), BECONASE AQ*
PROGRAM (RBP)
(QL,RBP), FLONASE* (QL,RBP), NASACORT AQ* (QL,RBP), NASAREL*
(QL,RBP), NASONEX* (QL,RBP), OMNARIS* (QL,RBP), RHINOCORT AQUA*
acetic acid, acetic acid-aluminum Women's Health Sprintec, Tri-Previfem, Trinessa, University of Arkansas January 2012 NOTE: If a product may be used to treat infertility prior authorization
RBP: PLAN WILL PAY $0.26/PILL; REMAINING COST WILL BE APPLIED TO
REFERENCE BASED PRICING PROGRAM (RBP)
ACTONEL (RBP), ATELVIA (RBP), BONIVA (RBP), FOSAMAX (RBP)
Miscellaneous
FOR YOUR INFORMATION: Generics should be considered the first line of prescribing. This drug list represents a summary of prescription coverage. It is not inclusive and does not guarantee coverage. Specific prescription benefit plan design may not cover certain categories, regardless of their appearance in this document. The plan participant’s prescription benefit plan may have a different copay for specific products on the list. Unless specifically indicated, drug list products will include all dosage forms. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics. Generics listed in therapeutic categories are for representational purposes only. This is not an all-inclusive list. Listed products may be available generically in certain strengths or dosage forms. Dosage forms on this list will be consistent with the category and use where listed. Log in to www.medimpact.com to check coverage and copay information for a specific medicine. 1 Copayment, copay or coinsurance means the amount a plan participant is required to pay for a prescription in accordance with a Plan, which may be a deductible, a percentage of the prescription price, a fixed amount or other charge, with the balance, if any, paid by a Plan. 2 Atacand should be reserved for plan participants who meet CHARM (Candesartan in Heart Failure – Assessment of Reduction in Mortality and Morbidity) trial criteria. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber.
Slutgiltigt Rally-PM för Spexets Rebusrally vÃ¥ren 2004 Det här är den slutgiltiga versionen av rally-PM. Ändringar och tillägg gentemot preliminärt rally-PM som funnits tillgängligt pÃ¥ nätet är här markerade med fet, understruken stil. D fir gegen ohne auto (D4GOA) ber att fÃ¥ hälsa er välkomna till vÃ¥rt första rebusrally nÃ¥gonsin! Även om ni deltagit förut, och lÃ
SRI SIDDHARTHA MEDICAL COLLEGE TUMKUR A CONSTITUENT COLLEGE OF SRI SIDDHARTHA UNIVERSITY, Papers Published in Indexed (Scopus) Journals ISSN (P) / ISSN E 1. Vijayaraghavan. R, Chandrashekar R, Belgavi CS .Inflammatory myofibroblastic tumour of appendix. J of Clin Pathol. 2006;59:999-1000. 2. Vijayaraghavan. R, Chandrashekar, Sujatha.Y , Belgavi CS . Hospital outbreak of a ty